Wutah pendapatan taun lumaku: Lixte Biotechnology, Inc. (LIXT)

Logo perusahaan publik lixte.com (LIXT)

Lixte Biotechnology is developing a network for creating LB-100 inhibitors through strategic alliances with scientific centers, while the success of its cancer therapy relies on medical efficacy rather than market cycles. This rolling annual sales growth chart reflects revenue dynamics, where the indicator value stands at 0.00. The company is currently funding early-stage tests using its existing cash reserves.

Lixte Biotechnology (LIXT): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 06.07.2026

Lixte Biotechnology - rincian analitis lan metrik utama (LIXT)

- rega saham lan target rega konsensus:
Ringkesan analitik perusahaan:Lixte Biotechnology Holdings
Produk merek Lixte Biotechnology, Inc.

Capital must distinguish fundamental growth from short-term speculation. The Lixte Biotechnology (LIXT) model, which outsources testing to external CRO partners, minimizes costs while maintaining control over patents. By analyzing the LTM sales growth YoY, an investor can see the percentage increase in revenue over a trailing twelve-month period. Daily data tracking on this chart allows for the immediate identification of abnormal spikes or trend reversals, confirming the actual resilience of the business's revenue.

Karo sapa Lixte Biotechnology saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CHRS (Coherus BioSciences)|Corbus Pharma - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur CRDF (cardiffoncology.com)|BYSI: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku BioAtla Corp (BCAB)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur